Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 7/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | AHR | P35869 | 3/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.40 |
| ▸ | F7 | P08709 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | F3 | P13726 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5114241 | 1.00 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3CYP2D6F2 | |
| SCHEMBL1465074 | 0.86 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3CYP2D6USP2 | |
| SCHEMBL12742656 | 0.84 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3CYP2D6USP2 | |
| SCHEMBL1465584 | 0.81 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3CYP2D6USP2 | |
| SCHEMBL14403866 | 0.81 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3CYP2D6USP2 | |
| SCHEMBL29535017 | 0.75 | HDAC6 (0.45) | F2USP2GAAALOX15RAD51 | |
| SCHEMBL19753243 | 0.71 | CYP2D6 (0.50) | SLC6A2SLC6A4SLC6A3CYP2D6USP2 | |
| SCHEMBL7003023 | 0.71 | CYP2D6 (0.50) | SLC6A2SLC6A4SLC6A3CYP2D6F2 | |
| SCHEMBL13365179 | 0.71 | HDAC1 (0.53) | HDAC1EPHX1 | |
| Formic Acid SCHEMBL29534961 | 0.71 | HDAC6 (0.41) | F2CYP2A6KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250332151-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | VERTEX PHARMA (US) | 2025-10-30 | — | — | US | claimed |
| EP-4525858-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | Vertex Pharmaceuticals Incorporated (US) | 2025-03-26 | — | — | EP | claimed |
| EP-4472635-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | Vertex Pharmaceuticals Incorporated (US) | 2024-12-11 | — | — | EP | claimed |
| WO-2023224931-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-11-23 | — | — | WO | claimed |
| WO-2023150237-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-10 | — | — | WO | claimed |
| EP-4525858-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | Vertex Pharmaceuticals Incorporated (US) | 2025-03-26 | — | — | EP | disclosed |
| EP-4472635-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | Vertex Pharmaceuticals Incorporated (US) | 2024-12-11 | — | — | EP | disclosed |
| WO-2023224931-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-11-23 | — | — | WO | disclosed |
| EP-4274828-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | AbbVie Global Enterprises Ltd. (BM) | 2023-11-15 | — | — | EP | disclosed |
| WO-2023150237-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-2022150174-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | AbbVie Global Enterprises Ltd. (BM) | 2022-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250332151-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | CFTR, SLC26A4, SLC26A3 | SLC6A2 407/4885SLC6A4 432/4885SLC6A3 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.